Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients

Leuk Res. 2011 Apr;35(4):429-30. doi: 10.1016/j.leukres.2010.10.012. Epub 2010 Nov 4.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Deoxycytidine Kinase / genetics*
  • Gene Expression Regulation, Enzymologic
  • Gene Expression Regulation, Leukemic
  • Humans
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / genetics*
  • Lymphopenia / chemically induced
  • Neutropenia / chemically induced
  • Polymorphism, Single Nucleotide*
  • Promoter Regions, Genetic / genetics
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives

Substances

  • Deoxycytidine Kinase
  • Vidarabine
  • fludarabine